Natural Compound Honokiol and Its Application against Fulvestrant-Resistant Breast Cancer Cells: An In Vitro Challenge-Reference-Cited by-同舟云学术

Natural Compound Honokiol and Its Application against Fulvestrant-Resistant Breast Cancer Cells: An In Vitro Challenge

Published:2023-12-12 Issue: Volume: Page:
ISSN:
Container-title:The 4th International Electronic Conference on Applied Sciences
language:
Short-container-title:

Author:

Mikhaevich Ekaterina I.¹,Sorokin Danila V.¹²,Bogdanov Fedor B.¹³^ORCID,Scherbakov Alexander M.¹²^ORCID

Affiliation:

1. Department of Experimental Tumor Biology, Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia, 115522 Moscow, Russia

2. Molecular Genetics Laboratory, Institute of Clinical Medicine, National Research Lobachevsky State University of Nizhny Novgorod, 603022 Nizhny Novgorod, Russia

3. Faculty of Medicine, Moscow State University, 119991 Moscow, Russia

Publisher

MDPI

Link

https://www.mdpi.com/2673-4591/56/1/141/pdf

Reference24 articles.

1. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020;Lei;Cancer Commun.,2021

2. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): An international, randomised, double-blind, phase 3 trial;Robertson;Lancet,2016

3. Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer;Kaklamani;Oncologist,2017

4. Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers;Williams;Cell Death Dis.,2018

5. Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer;Kaminska;Breast Cancer Res.,2021